|
|
|
|
| LEADER |
00000cam a2200000Ia 4500 |
| 001 |
SCIDIR_on1306276987 |
| 003 |
OCoLC |
| 005 |
20231120010638.0 |
| 006 |
m o d |
| 007 |
cr un|---aucuu |
| 008 |
220330s2022 enk o 000 0 eng d |
| 040 |
|
|
|a YDX
|b eng
|c YDX
|d OPELS
|d EBLCP
|d OCLCO
|d OCLCF
|d OCLCQ
|d OCLCO
|
| 020 |
|
|
|a 9780323858762
|q (electronic bk.)
|
| 020 |
|
|
|a 0323858767
|q (electronic bk.)
|
| 020 |
|
|
|z 9780323858731
|
| 020 |
|
|
|z 0323858732
|
| 035 |
|
|
|a (OCoLC)1306276987
|
| 050 |
|
4 |
|a RS199.5
|
| 082 |
0 |
4 |
|a 615/.6
|2 23
|
| 245 |
0 |
0 |
|a Combination drug delivery approach as an effective therapy for various diseases /
|c edited by Prashant Kesharwani.
|
| 260 |
|
|
|a London :
|b Academic Press,
|c 2022.
|
| 300 |
|
|
|a 1 online resource
|
| 505 |
0 |
|
|a Front Cover -- Combination Drug Delivery Approach as an Effective Therapy for Various Diseases -- Copyright Page -- Dedication -- Contents -- List of contributors -- Preface -- Acknowledgments -- A. Combination drug delivery approaches against various diseases -- 1 Overcoming cancer drug resistance via nanomedicine-based combined drug delivery -- 1.1 Introduction -- 1.2 Organic nanocarriers -- 1.2.1 Lipid-based systems -- 1.2.1.1 Liposomal formulations -- 1.2.1.2 Solid lipid nanoparticles -- 1.2.1.3 Nanostructured lipid carriers -- 1.2.1.4 Nanoemulsion -- 1.2.2 Protein-based nanocarriers
|
| 505 |
8 |
|
|a 1.2.3 Polymeric nanoparticles -- 1.3 Inorganic nanocarriers -- 1.3.1 Iron oxide nanoparticles -- 1.3.2 Quantum dots -- 1.3.3 Gold nanoparticles -- 1.3.4 Mesoporous silica nanoparticles -- 1.3.5 Carbon-based nanocarriers -- 1.3.5.1 Graphene -- 1.3.5.2 Carbon nanotubes -- 1.4 Conclusion -- References -- 2 Overcoming the challenges of drug resistance through combination drug delivery approach -- 2.1 Introduction -- 2.2 Drug resistance in cancer -- 2.2.1 Intrinsic and acquired drug resistance -- 2.2.2 Mechanisms of drug resistance -- 2.2.2.1 Elevated drug efflux -- 2.2.2.2 Tumor microenvironment
|
| 505 |
8 |
|
|a 2.2.2.3 Enhanced DNA repair -- 2.2.2.4 Other mechanisms -- 2.2.3 Combinational drug delivery systems in cancer drug resistance -- 2.2.3.1 Nanoparticulate drug delivery systems -- 2.2.4 Combinational therapies via nanoparticulate systems -- 2.2.4.1 Combination of different chemotherapeutics -- 2.2.4.2 Combination of chemotherapeutics and sensitizing agents -- 2.2.4.2.1 P-gp inhibitors -- 2.2.4.2.2 Autophagy inhibitors -- 2.2.4.3 Combination of chemotherapeutics and genes -- 2.2.4.3.1 Plasmid DNA -- 2.2.4.3.2 RNAs -- 2.2.4.4 Combination of chemotherapeutics and protein-based molecules
|
| 505 |
8 |
|
|a 2.2.4.4.1 Antibodies -- 2.2.4.4.2 Peptides and proteins -- 2.2.5 Conclusion -- 2.3 Combination drug delivery approach to overcome antimicrobial resistance -- 2.4 Conclusion -- References -- 3 Combination drug delivery approaches in ophthalmology -- 3.1 The eye -- 3.2 The need for new ophthalmic treatments -- 3.2.1 Increasing prevalence of ocular diseases -- 3.2.1.1 Age as risk factor -- 3.2.1.2 Susceptibility to exogenous threats -- 3.2.1.3 Refractive surgery for myopia -- 3.2.2 The difficulty of drugs to reach their intraocular target
|
| 505 |
8 |
|
|a 3.2.3 Adverse ocular effects of topically administered drugs -- 3.3 Drug-device combinations in ophthalmology -- 3.3.1 Drug-device combinations for glaucoma -- 3.3.2 Drug-device combinations for surgeries -- 3.3.3 Drug-device combinations for ocular infections and inflammations -- 3.3.4 Drug-device combinations for dry eye disease -- 3.4 Challenges and future perspectives -- References -- 4 Combination drug delivery system to enhance the transdermal drug delivery of bioactive molecules -- 4.1 Introduction -- 4.2 Physiological skin row versus percutaneous permeation of bioactive molecules
|
| 650 |
|
0 |
|a Drug delivery systems.
|
| 650 |
|
0 |
|a Chemotherapy.
|
| 650 |
|
2 |
|a Drug Delivery Systems
|0 (DNLM)D016503
|
| 650 |
|
2 |
|a Drug Therapy
|0 (DNLM)D004358
|
| 650 |
|
6 |
|a Syst�emes d'administration de m�edicaments.
|0 (CaQQLa)000260397
|
| 650 |
|
6 |
|a Chimioth�erapie.
|0 (CaQQLa)201-0034750
|
| 650 |
|
7 |
|a Chemotherapy
|2 fast
|0 (OCoLC)fst00853595
|
| 650 |
|
7 |
|a Drug delivery systems
|2 fast
|0 (OCoLC)fst00898667
|
| 700 |
1 |
|
|a Kesharwani, Prashant.
|
| 776 |
0 |
8 |
|c Original
|z 0323858732
|z 9780323858731
|w (OCoLC)1268112830
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780323858731
|z Texto completo
|
